by Maria Zannes | Aug 13, 2025 | Press Releases
July Test Volume Surges 72% Over Prior Monthly Average SAN ANTONIO, TX – August 13, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced a significant surge...
by Maria Zannes | Jul 29, 2025 | Press Releases
bioAffinity Technologies’ noninvasive sputum test catches rare cancer in time for curative surgery SAN ANTONIO, TX – July 29, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer...
by Maria Zannes | Jul 23, 2025 | Press Releases
bioAffinity Technologies’ noninvasive sputum test flagged difficult-to-diagnose cancer at earliest Stage 1A SAN ANTONIO, TX – July 23, 2025 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need for noninvasive, accurate...
by Maria Zannes | Jul 22, 2025 | Press Releases
New patent protects market expansion to the north where lung cancer is leading cause of cancer deaths SAN ANTONIO, TX — July 22, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including...
by Maria Zannes | Jul 15, 2025 | Press Releases
One third of world’s smokers live in China, which has highest rate of lung cancer SAN ANTONIO, TX — July 15, 2025 — bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company advancing early-stage cancer diagnostics including CyPath® Lung, the...
by Maria Zannes | Jul 9, 2025 | Press Releases
bioAffinity Technologies’ noninvasive sputum test revealed early-stage lung cancer when other diagnostic options were contraindicated SAN ANTONIO, Texas (July 9, 2025) – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company addressing the need...
